Optimal therapeutic efficacy of ␤-lactam antibiotics for treatment of pneumococcal pneumonia is thought to be associated with the serum concentration greater than the minimum inhibitory concentration for 40 -50% of the interdose interval at site of infection. Objective: Establish whether intravenous administration of ampicillin 400 mg/kg/day or penicillin 200,000 IU/kg/day in 6 divided doses reaches serum and or pleural concentrations above 4 g/ml for at least 40% of the interdose interval. Materials and Methods: Hospitalized healthy children 1month-14 years old with community-acquired bacterial pneumonia and empyema were eligible. Blood samples were obtained 30 min (C1) and 3 h (C2) after an antibiotic dose. Pleural fluid samples were obtained 1 and 4 h after the same dose in which blood samples were obtained. The concentrations were measured by high performance liquid chromatography. Results: The study included 17 patients treated with ampicillin and 13 treated with penicillin. For ampicillin, mean serum concentrations were C1 37.3 Ϯ 19 g/ml and C2 11 Ϯ 10.2 g/ml and mean pleural fluid concentrations were C1 25.8 Ϯ 9.9 g/ml and C2 16.2 Ϯ 7.9 g/ml. For penicillin, mean serum concentrations were C1 21.8 Ϯ 16.4 g/ml and C2 23.9 Ϯ 3.4 g/ml. Mean pleural fluid concentrations were C1 10.9 Ϯ 2.2 g/ml and C2 7.7 Ϯ 3.4 g/ml. In 8 of 30 patients, serum C2 was Ͻ4 g/ml; in all of them serum concentrations were Ͼ4 g/ml for Ͼ40% of the interdose interval. Conclusions: This study of the pharmacokinetics of ␤-lactam antibiotics in children with bacterial pneumonia may help in the devel-
C
hildhood lower respiratory tract infections of bacterial and viral origin are still responsible for substantial morbidity and mortality and are the most frequent cause of hospital admission during winter months in nontropical countries. [1] [2] [3] Children with community-acquired bacterial pneumonia (CABP) may present life-threatening complications such as sepsis or empyema. 4, 5 Treatment of children with CABP is frequently revised worldwide in response to changes in antibiotic susceptibilities. 6 -12 No therapeutic failures have been proved with high doses of ␤-lactam antibiotics as treatment of pneumococcal pneumonia caused by strains with a minimum inhibitory concentration (MIC) Ͻ2 g/ml. [5] [6] [7] 13 Considering this evidence, the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group has recommended consideration of pneumococcal strains in patients with pneumonia as susceptible at MIC Յ 1 g/ml, intermediate at MIC ϭ 2 and resistant at MIC Ն 4 g/ml. 7 In Uruguay, a South American country with a population of 3,000,000 people, S. pneumoniae is the most frequent cause of CABP since the Haemophilus influenzae type b vaccine was included in the obligatory immunization schedule.
14 Staphylococcus aureus exceptionally causes CABP. Thus empiric antibiotic treatment in children with CABP is focused against S. pneumoniae. 15 In 1996, 40% of S. pneumoniae strains had reduced susceptibility to penicillin and almost 20% to third generation cephalosporins. 16 In 1997, guidelines for diagnosis and treatment of hospitalized chil-dren with CABP were developed and have been applied since. Large intravenous dosages of ampicillin (300 -400 mg/kg/day) or penicillin (200,000 IU/kg/day) are recommended as empiric antibiotic treatment. 4 Periodic evaluation of these guidelines has shown successful treatment of children with CABP caused by S. pneumoniae strains with reduced susceptibility to penicillin. 4, 17 In animal models, large dosages of ␤-lactam antibiotics administered intravenously reach concentrations Ͼ4 g/ml in both serum and pleural fluid. 18 -20,23 The time the antibiotic is present at concentrations greater than the MIC (T Ͼ MIC) is the major pharmacodynamic factor correlated with the efficacy of ␤-lactam antibiotics. The optimal therapeutic efficacy of ␤-lactam antibiotics in the treatment of pneumococcal pneumonia is associated with a T Ͼ MIC ϭ 40 -50% of the interdose interval. 18 -23 The knowledge of these pharmacokinetic parameters in children may contribute to the most rational use of ␤-lactam antibiotics in CABP.
In this study, we sought to evaluate whether intravenous administration of ampicillin at 400 mg/kg/day or penicillin at 200,000 IU/kg/day in 6 divided doses reaches serum and/or pleural concentrations Ͼ4 g/ml for at least 40% of the interdose interval.
MATERIALS AND METHODS
Healthy pediatric patients 1 month-14 years old with CABP and empyema treated according to standard guidelines, hospitalized in the Centro Hospitalario Pereira Rossell, Montevideo, Uruguay, were eligible for entry into the study. Chest tubes had been inserted for the routine care of the patients. Exclusion criteria included multiorgan failure, cystic fibrosis, hypersensitivity to ␤-lactam antibiotics, renal dysfunction, immunodeficiency and simultaneous administration of other drugs with the exception of antipyretics. Children with appreciable alterations in body fluids, pneumothorax or bronchopleural fistula were also excluded. Written informed consent was obtained from a parent or guardian of each patient before enrollment into the study. The study protocol was approved by the Ethics Committee of the Facultad de Medicina, Universidad de la República, Montevideo.
Ampicillin was administered intravenously as a bolus in a dosage of 400 mg/kg/day in 6 divided doses. Penicillin was administered as an intravenous infusion in 20 min at 200,000 IU/kg/day in 6 divided doses. Blood samples were obtained 30 min (C1) and 3 h (C2) after the end of the antibiotic dose. Pleural fluid samples were obtained 1 and 4 h after the same dose in which blood samples were obtained. Blood and pleural fluid samples of at least 5 mL were centrifuged at 3000 rpm and then stored at Ϫ20°C; penicillin assay was performed 6 -56 days (mean 20) later and ampicillin assay 40 -342 days (mean, 262) later, at Allquimia Laboratory, Montevideo, Uruguay.
Ampicillin and penicillin concentrations in serum and pleural fluid were measured by high performance liquid chromatography with ultraviolet (UV) detection. The method consisted of extracting ampicillin and penicillin from serum and pleural fluid by adding primidone (100 g/ml) and carbamazepine (100 g/ml) as an internal standard after protein precipitation by acetonitrile. The mobile phase was a solution of 0.05M KH 2 PO 4 (95%) and acetonitrile (5%) at pH 6.2. 24 -26 A reversed phase C 8 column and UV wave length of 201 nm were used. The linearity of the method was demonstrated in the range of 1.8 to 268 g/ml for ampicillin and in the range of 1.3 to 394.3 g/ml for penicillin. The lower limit of detection of the method was 1.0 g/ml for ampicillin and 0.4 g/ml for penicillin.
The pharmacokinetic indices were calculated on the basis of an open 1-compartment model. The ampicillin or penicillin distribution was estimated to be complete in 30 min. Half-life in serum and pleural fluid of the drugs (t ͓1/2͔ ) was calculated as ln 2/K, where K is the elimination rate constant. K was determined as (ln C2 Ϫ ln C1)/⌬t, C2 being the serum concentration at h 3 (t 2 ), C1 the serum concentration 30 min (t 1 ) after a dose and ⌬t the difference between t 2 and t 1 . In those cases in which the serum concentration 3 h after a dose was Ͻ4 g/ml, the time in which its value was Ͼ4 g/ml was estimated as t 4 
The serum concentration 6 h after dose (C 6 ) was estimated as C 0 ϭ C 1 /e Ϫt1·k ϫ (͓1/ 2͔) n , n being the number of t ͓1/2͔ after a dose.
RESULTS
From May 2001 to March 2003, 33 hospitalized children with CABP and empyema were included; 17 were treated with ampicillin and 13 with penicillin. Three patients (2 treated with ampicillin and 1 with penicillin) were excluded from the study because of problems in the coordination of sample extraction. The children's mean age was 3 years and 11 months (range, 9 months-14 years); 16 were boys; 27 were well-nourished. The duration of illness before hospital admission was on average 5.2 days (range, 1 to 10).
S. pneumoniae was isolated from blood and/or pleural fluid in 8 patients; the rest of the cultures were negative. All S. pneumoniae strains were susceptible to penicillin (MIC Յ 0.01 g/ml).
Most of the patients (n ϭ 22) received 6 or more antibiotic doses previous to sample collection. In the others, the number of previous doses was 5 (n ϭ 1), 4 (n ϭ 4), 3 (n ϭ 1) or 1 (n ϭ 2).
The concentrations of ampicillin in serum and pleural fluid and the estimated half-life are shown in Table 1 . In 4 patients (patients 7, 8, 11 and 12) C2 was Ͻ4 g/ml; in 1 patient (patient 3) serum concentration 3 h after the dose (C2) was below the detection limit (1.0 g/ml). Two pleural fluid
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samples were obtained in 9 patients and 1 sample in 3 patients; it was not possible to obtain a sample in 5. Penicillin serum and pleural fluid concentrations and half-life are shown in Table 2 . Two pleural fluid samples were obtained in only 4 patients treated with penicillin.
In 6 of 13 patients treated with penicillin, serum concentrations 3 h after the dose (C2) were below the detection limit (0.4 g/ml). In 8 of 30 patients, overall C2 was above the detection limit but still Ͻ4 g/ml (4 of 17 patients treated with ampicillin and 4 of 13 treated with penicillin). Table 3 shows the time during which serum concentrations in these 8 patients was Ͼ4 g/ml; in all patients, it was Ͼ40% of the interdose interval. Table 4 shows the extrapolated C6 of ampicillin and penicillin; in 17 of 22 patients (12 of 15 treated with ampicillin and 5 of 7 treated with penicillin), the time during which serum concentrations were Ͼ4 g/ml was Ͼ40% of the interdose interval.
The mean duration of hospitalization was 14 days (range, 3-30 days). No patient died. Two patients had complications that required thoracotomy: patient 11 developed an abscess in the superior lobe of the right lung; patient 17 had a loculated empyema; and patient 20 developed a bronchopleural fistula.
DISCUSSION
In Uruguay, from 1994 through 2000, 31% of the pneumococcal isolates from children showed reduced susceptibility to penicillin (17% intermediate and 14% resis- 
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␤-Lactams in Serum and Pleura Fluid tant). 27, 28 The highest percentage of reduced susceptibility was observed among patients with pneumonia.
Resistance rates to penicillin have not changed since 1997 28 -30 ; all isolates in this study were susceptible to penicillin.
Children with pneumococcal pneumonia caused by intermediate susceptibility strains (MIC 2 g/ml) and resistant strains (MIC Ն 4 g/ml) have been successfully treated with high ampicillin doses. 4, 17, 29, 30 Although ampicillin and penicillin are the first line antibiotics for empiric treatment of CABP, there is no consensus related to dose and dose interval. [31] [32] [33] An answer to this problem requires the knowledge of serum and pleural fluid concentrations reached by these antibiotics with different dose regimens, but little information is available regarding this. 34, 35 Our results confirm that intravenous ampicillin given as 400 mg/kg/day, divided every 4 h, reaches serum concentrations that largely exceed 4 g/ml 30 min after a dose. In most children, the serum concentration remained above 4 g/ml 3 h after the dose. The median of serum t 1/2 estimated in this population concurs with that described by others. 21 Pharmacokinetics alone do not predict treatment efficacy of antibiotics. Serum and tissue antibiotic concentrations do not always correlate with the pathogen elimination rate and do not take into account possible postantibiotic effects. Pharmacokinetic/pharmacodynamic factors that have a better correlation with the antibacterial activity have been derived from animal studies. 20, 22, 23 Antimicrobial activity of ␤-lactam antibiotics is timedependent. The pharmacokinetic/pharmacodynamic factor that correlates best with the bacteriologic and clinical efficacy is the time during which serum concentrations remain over the MIC (T Ͼ MIC) of the pathogen. Optimal elimination rates are obtained when adequate antibiotic concentration is maintained at the site of infection for longer periods of time. [13] [14] [15] [16] In the case of S. pneumoniae, the therapeutic efficacy is best correlated with a T Ͼ MIC of 40-50% of the dosing interval. 22, [33] [34] [35] In most of the patients with the ampicillin dose used in our study, the T Ͼ MIC was Ͼ75% of the dosing interval (3 h). In the 4 patients who had serum concentrations of Ͻ4 g/ml 3 h after a dose, T Ͼ MIC was Ͼ50% of the dosing interval in 3 and 50% in 1. Clinical outcome was good in all the patients.
All patients treated with penicillin had maximum serum concentrations Ͼ4 g/ml. In most patients, serum concentrations 3 h after the dose were Ͻ4 g/ml. The T Ͼ MIC was Ͼ40% of the dosing interval in 7 of the 13 patients treated with penicillin.
The pleural fluid concentrations were Ͼ4 g/ml during the entire dosing interval in most children in whom it could be determined. The t 1/2 of ampicillin in pleural fluid was greater than the t 1/2 in serum. In 3 of 4 patients treated with penicillin from whom pleural samples were obtained, the concentrations were almost constant during the entire dosing interval. It is possible that the distribution of these antibiotics in lung tissue and their slow excretion from the pleural compartment explain the high concentrations observed in pleural fluid in some children as it was described for the animal models. 20 It is not uncommon for other institutions to administer the antibiotics every 6 h. Our extrapolated data show that the T Ͼ MIC might be Ͼ40% if the dosing interval was 6 h in most of the patients treated with ampicillin at 400 mg/kg/day, but in most of the patients treated with penicillin at 200,000 IU/kg/day the T Ͼ MIC was not Ͼ40% if the dosing interval was 6 h.
Considering that in our country most pneumococcal strains with reduced susceptibility to penicillin have MIC Ͻ4 g/ml, these results support the continued use of our treatment guidelines, which recommend intravenous ampicillin at 400 mg/kg/day or penicillin at 200,000 units/kg/day in 6 divided doses for the empiric treatment of CABP when S. pneumoniae is the suspected etiology. In third world countries, the possibility of using a low cost antibiotic with high efficacy has at least 2 advantages: it favors a reduction in the health care costs; and it may help to control the increase of resistant bacterial strains.
